Juniper Pharmaceuticals, Inc. Common Stock
JNP
JNP was delisted on the 13th of August, 2018.
40 hedge funds and large institutions have $19.9M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 7 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
0.58% less ownership
Funds ownership: 33.41% → 32.83% (-0.58%)
1% less capital invested
Capital invested by funds: $20.1M → $19.9M (-$249K)
13% less funds holding
Funds holding: 46 → 40 (-6)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$299K |
| 2 |
Renaissance Technologies
New York
|
+$98.3K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$26.6K |
| 4 |
AG
Algert Global
San Francisco,
California
|
+$23.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EGA
Eagle Global Advisors
Houston,
Texas
|
-$247K |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$201K |
| 3 |
PCM
Perritt Capital Management
Chicago,
Illinois
|
-$155K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$73.2K |
| 5 |
Bank of New York Mellon
New York
|
-$59K |
JNP Hedge Fund Activity: Q4 2016 in Review
40 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q4 2016, worth a combined $19.9M — down 1.2% from $20.1M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of JNP and 2 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 12 added.
The largest buyer was Stonepine Capital Management, adding an estimated $299K. The largest seller was Eagle Global Advisors, exiting entirely with an estimated $247K sold.
- 40 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q4 2016, down from 46 in Q3 2016.
- Funds reported $19.9M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q4 2016, down 1.2% quarter-over-quarter.
- 2 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q4 2016 and 7 closed out, a net change of -5 holders.
- The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q4 2016 was Stonepine Capital Management, an estimated $299K added.
- The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q4 2016 was Eagle Global Advisors, an estimated $247K sold.
Based on aggregated 13F filings for Q4 2016.